New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes

Acta Clinica Belgica

Volumn 61, Issue 5, 2006, Pages 275-285

  Keymeulen, Bart ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Islet transplantation; Prevention; Type 1 diabetes

Indexed keywords

C PEPTIDE; CALCINEURIN INHIBITOR; CHAGLYCD3 ANTIBODY; CYCLOSPORIN; INSULIN; INSULIN ZINC SUSPENSION; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OKT 3; PLACEBO; TACROLIMUS; THYMOCYTE ANTIBODY;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG MECHANISM; FLU LIKE SYNDROME; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY ALLOGRAFT REJECTION; METABOLIC REGULATION; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PREVENTIVE MEDICINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; XENOTRANSPLANTATION;

EID: 33845490634     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2006.047     Document Type: Conference Paper

References (83)

1. Gorus FK. Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 1997;13(4):247-74.
2. Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 1965;14(10):619-33.
3. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 1981;70(1):105-15.
4. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992;8(3):209-27.
5. Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994;15(4):516-42.
6. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993;329(14), 977-986.
7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005;353(25), 2643-2653.
8. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53(1):250-64.
9. Bingley PJ, Colman P, Eisenbarth GS, Jackson RA, McCulloch DK, Riley WJ et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992;15(10):1313-6.
10. Srikanta S, Ganda OP, Jackson RA, Gleason RE, Kaldany A, Garovoy MR et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983;99(3):320-6.
11. Ganda, OP, Srikanta, S, Brink, SJ, Morris, MA, Gleason, RE, Soeldner, JS, and Eisenbarth, GS. Differential sensitivity to beta-cell secretagogues in "early," type I diabetes mellitus. Diabetes 1994;33(6), 516-521.
12. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237(3):E214-23.
13. Gjessing HJ, Reinholdt B, Faber OK, Pedersen O. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1991;124(5):556-62.
14. Greenbaum CJ, Cuthbertson D, Krischer JP. Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 2001;50(2):470-6.
15. Chaillous L, Rohmer V, Maugendre D, Lecomte P, Marechaud R, Marre M et al. Differential beta-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus. Metabolism 1996;45(3)306-14.
16. Madsbad S, Krarup T, Faber OK, Binder C, Regeur L. The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1982;22(1):16-20.
17. Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark A, Sundkvist G et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988;31(9):664-9.
18. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 1999;84(5):1534-9.
19. Decochez K, Keymeulen B, Somers G, Dorchy H, De Leeuw IH, Mathieu C et al. Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care 2000;23(8):1072-8.
20. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352(25):2598-608.
21. Weets I, Truyen I, Verschraegen I, Van der Auwera B, De Schepper J, Dorchy H et al. Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 2006;49(6):1158-62.
22. Effect of Intensive Therapy on Residual {beta}-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial: A Randomized, Controlled Trial. Ann Intern Med 1998;128(7), 517-523.
23. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29(3):643-9.
24. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003;19(1):8-31.
25. Viskari H, Ludvigsson J, Uibo R, Salur L, Marciulionyte D, Hermann R et al. Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia 2005;48(7):1280-7.
26. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003;290(13):1721-8.
27. Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia 2005;48(5):829-37.
28. Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Bottazzo GF et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2(8260-61):1363-5.
29. Decochez K, De Leeuw IH, Keymeulen B, Mathieu C, Rottiers R, Weets I et al. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetologia 2002;45(12):1658-66.
30. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363(9413):925-31.
31. Effects of insulin in relatives of patients with type 1 diabetes meltitus. N Engl J Med 2002;346(22):1685-91.
32. Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 2003;46(3):339-46.
33. Schatz D, Cuthbertson D, Atkinson M, Salzler MC, Winter W, Muir A et al. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus-a new surrogate measure of non-progression? Pediatr Diabetes 2004;5(2):72-9.
34. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991;34(5):362-5.
35. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993;341(8850):927-8.
36. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998;41(5):536-41.
37. Shoda LK, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005;23(2):115-26.
38. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26(3):832-6.
39. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986;2(8499):119-24.
40. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988;37(11):1574-82.
41. Russell PS, Colvin RB, Cosimi AB. Monoclonal antibodies for the diagnosis and treatment of transplant rejection. Annu Rev Med 1984;35:63-81.
42. Chatenoud L, Ferran C, Bach JF. In-vivo anti-CD3 treatment of autoimmune patients. Lancet 1989;2(8655):164.
43. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994;91(1):123-7.
44. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-8.
45. Routledge EG, Falconer ME, Pope H, Lloyd IS, Waldmann H. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 1995;60(8):847-53.
46. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003;3(2):123-32.
47. Cohen DJ, St Martin L, Christensen LL, Bloom RD, Sung RS. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006;6(5 Pt 2):1153-69.
48. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003;290(21):2817-23.
49. Lacy PE. Treating diabetes with transplanted cells. Sci Am 1995;273(1):50-1, 54-8.
50. Pipeleers D, Keymeulen B Korbutt G. Islet transplantation. Diabetes Annual 1994; 9, 299-330.
51. Lacy PE, Davie JM, Finke EH. Prolongation of islet allograft survival following in vitro culture (24 degrees C) and a single injection of ALS. Science 1979;204(4390):312-3.
52. Thomson AW, Mazariegos GV, Reyes J, Donnenberg VS, Donnenberg AD, Bentlejewski C et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 2001;72(8 Suppl):S13-22.
53. Pipeleers DG, Pipeleers-Marichal M, Vanbrabandt B, Duys S. Transplantation of purified islet cells in diabetic rats. II. Immunogenicity of allografted islet beta-cells. Diabetes 1991;40(7):920-30.
54. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65.
55. Ricordi C, Strom TB. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 2004;4(4):259-68.
56. Warnock GL, Kneteman NM, Ryan EA, Rabinovitch A, Rajotte RV. Long-term follow-up after transplantation of insulin-producing pancreatic islets into patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992;35(1):89-95.
57. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Boyle PJ et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991;51(1):76-85.
58. Keymeulen B, Ling Z, Gorus FK, Delvaux G, Bouwens L, Grupping A et al. Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia 1998;41(4):452-9.
59. Hering BJ, Browatzki CC, SchultzA, Bretzel RG, Federlin KF. Clinical islet transplantation-registry report, accomplishments in the past and future research needs. Cell Transplant 1993;2(4):269-82; discussion 283-305.
60. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343(4):230-8.
61. Shapiro, AM, Ricordi C, Hering, B., Auchincloss H, Lindblad R, Robertson R.P et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355(13), 1318-1330.
62. Movahedi B, Keymeulen B, Lauwers MH, Goes E, Cools N, Delvaux G. Laparoscopic approach for human islet transplantation into a defined liver segment in type-1 diabetic patients. Transpl Int 2003;16(3):186-90.
63. Maleux G, Gillard P, Keymeulen B, Pipeleers D, Ling Z, Heye S et al. Feasibility, safety, and efficacy of percutaneous transhepatic injection of beta-cell grafts. J Vasc Interv Radiol 2005;16(12):1693-7.
64. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005;54(7):2060-9.
65. Roep BO, Stobbe I, Duinkerken G, van Rood JJ, Lernmark A, Keymeulen B et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48(3):484-90.
66. Pinkse GG, Tysma OH, Bergen CA, Kester MG, Ossendorp F, van Veelen PA et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci USA 2005;102(51):18425-30.
67. Sutherland DE, Goetz FC, Sibley RK. Recurrence of disease in pancreas transplants. Diabetes 1989;38 Suppl 1:85-7.
68. Keymeulen B, Korbutt C, De Paepe M, Gorus F, Kloppel G, Pipeleers DG. Long-term metabolic control by rat islet grafts depends on the composition of the implant. Diabetes 1996;45(12):1814-21.
69. Decochez K, Truyen I, van der Auwera B, Weets I, Vandemeulebroucke E, de Leeuw IH et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005;48(4):687-94.
70. Truyen I, De Pauw P, Jorgensen PN, Van Schravendijk C, Ubani O, Decochez K et al. Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 2005;48(11):2322-9.
71. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005;54 Suppl 2: S62-7.
72. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005;48(11):2206-12.
73. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350(9087):1288-93.
74. Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 2005;48(4):703-8.
75. Kenyon NS, Chatzipetrou M, Masetti M, Ranuncoli A, Oliveira M, Wagner JL et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A 1999;96(14):8132-7.
76. Kenyon NS, Fernandez LA, Lehmann R, Masetti M, Ranuncoli A, Chatzipetrou M et al. Long-term survival and function of intrahepatic islet allografts in baboons treated with humanized anti-CD154. Diabetes 1999;48(7):1473-81.
77. Schuler W, Bigaud M, Brinkmann V, Di Padova F, Geisse S, Gram H et al. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004;77(5):717-26.
78. Maki T, Ichikawa T, Blanco R, Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A 1992;89(8):3434-8.
79. Bogdani M, Suenens K, Bock T, Pipeleers-Marichal M, In't Veld P, Pipeleers D. Growth and functional maturation of beta-cells in implants of endocrine cells purified from prenatal porcine pancreas. Diabetes 2005;54(12):3387-94.
80. Veld PI, Pavlovic D, Bogdani M, Pipeleers-Marichal M, Pipeleers D. Xenotransplantation of purified pre-natal porcine beta cells in mice normalizes diabetes when a short anti-CD4-CD8 antibody treatment is combined with transient insulin injections. Xenotransplantation 2006;13(5):415-22.
81. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, Jiang W et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006;12(3):304-6.
82. Hering BJ, Wijkstrom M, Graham ML, Hardstedt M, Aasheim TC, Jie T et al. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med 2006;12(3):301-3.
83. Jeffcoate W. Drive to eliminate the burden of type 1 diabetes. Lancet 2006;367(9513):795-7.